The guidance notes that the remit only includes adults previously treated with sunitinib, and therefore the use of axitinib after treatment with other tyrosine kinase inhibitors is not subject to statutory funding.
At the time of publication, axitinib was only licensed for use after failure of first-line sunitinib or a cytokine. If it is considered for use after any other first-line treatments, the prescriber should obtain and document informed consent and follow the General Medical Council guidance on prescribing unlicensed medicines.